[
  {
    "ts": null,
    "headline": "Strong Results and Pipeline Momentum Power Amgen’s (AMGN) 2025 Rally",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial results and steady clinical progress, even as investors keep an eye on upcoming patent expirations. The stock is up more than 27% since the start […]",
    "url": "https://finnhub.io/api/news?id=0eb127c06e0a6718dd0cc98f741b46a1080fec8dedeb86831a9d17f589979a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767134672,
      "headline": "Strong Results and Pipeline Momentum Power Amgen’s (AMGN) 2025 Rally",
      "id": 137950362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial results and steady clinical progress, even as investors keep an eye on upcoming patent expirations. The stock is up more than 27% since the start […]",
      "url": "https://finnhub.io/api/news?id=0eb127c06e0a6718dd0cc98f741b46a1080fec8dedeb86831a9d17f589979a0b"
    }
  },
  {
    "ts": null,
    "headline": "BMY vs AMGN: Which Biotech Stock Is More Resilient Now?",
    "summary": "AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.",
    "url": "https://finnhub.io/api/news?id=fb26d8e8074750d7c719c4a173a8088ffa55da5a5f4fd470ed52b49edf6cbe52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767118920,
      "headline": "BMY vs AMGN: Which Biotech Stock Is More Resilient Now?",
      "id": 137943948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.",
      "url": "https://finnhub.io/api/news?id=fb26d8e8074750d7c719c4a173a8088ffa55da5a5f4fd470ed52b49edf6cbe52"
    }
  },
  {
    "ts": null,
    "headline": "Can Amgen's MariTide Take on Leaders in the Obesity Space?",
    "summary": "AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.",
    "url": "https://finnhub.io/api/news?id=a1a8a5dd8f79cd78f72609ffe69f46f1c8d5e146f44732d4f13c3267259bc1fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767110700,
      "headline": "Can Amgen's MariTide Take on Leaders in the Obesity Space?",
      "id": 137943085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.",
      "url": "https://finnhub.io/api/news?id=a1a8a5dd8f79cd78f72609ffe69f46f1c8d5e146f44732d4f13c3267259bc1fc"
    }
  },
  {
    "ts": null,
    "headline": "Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC",
    "summary": "Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts and the company's strong cash position.",
    "url": "https://finnhub.io/api/news?id=99fab1b6d59914d1f229fcacc8fd461b614d83ccd5fd9b30f6b447720f60347b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767109045,
      "headline": "Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC",
      "id": 137944095,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248270095/image_2248270095.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts and the company's strong cash position.",
      "url": "https://finnhub.io/api/news?id=99fab1b6d59914d1f229fcacc8fd461b614d83ccd5fd9b30f6b447720f60347b"
    }
  }
]